Blogs | MedChemExpress

Asunercept (APG101) is a Selective CD95L Inhibitor for Glioblastoma Research

Asunercept (APG101) is a soluble CD95-Fc fusion protein targeting CD95L.
Efineptakin alfa (NT-17) is a Long-Acting Recombinant Human IL-7 for Glioblastoma Research

Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa can be used for glioblastoma research.
Coibamide A, an Cytotoxic Depsipeptide, Induces Autophagosome Accumulation

Coibamide A is an N-methyl-stabilized cytotoxic depsipeptide with antiproliferative activity. Coibamide A induces autophagosome accumulation.
AZ31 is a Highly Selective and Orally Active ATM Inhibitor

AZ31 is a potent, highly selective, and orally active ATM inhibitor, and is also a potent radiosensitizer in vitro.
FPDT is an anti-glioblastoma agent and shows anti-glioblastoma activity by AKT pathway.

FPDT is an anti-glioblastoma agent. Besides, FPDT shows anti-proliferative activity for GBM cells and astrocytes.
Indoximod, An Immunometabolic Adjuvant, is an IDO Pathway Inhibitor

Indoximod, an immunometabolic adjuvant, is an orally active IDO pathway inhibitor. Indoximod acts as a Trp mimetic in regulating mTOR.
AZD1390 is a Highly Selective, Orally Active and Brain-Penetrant ATM Inhibitor

AZD1390 is a potent, highly selective, orally bioavailable, brain-penetrant ATM inhibitor with an IC50 of 0.78 nM.
PINT87aa, a Potential Tumor-Suppressive Peptide, Directly Interacts with the PAF1 Complex

PINT87aa, a potential tumor-suppressive peptide, directly interacts with the PAF1 complex and inhibits mRNA transcriptional elongation.
AMG-458 is a Selective and Orally Bioavailable c-Met Inhibitor

AMG-458 is a potent, selective and orally bioavailable c-Met inhibitor with potent anti-tumor activity in the NIH3T3/TPR-Met and U-87 MG xenograft models.
TED-347 is an Irreversible and Covalent YAP-TEAD Protein-Protein Interaction Inhibitor

TED-347 is a potent, irreversible, covalent and allosteric inhibitor at YAP-TEAD protein-protein interaction with antitumor activity.

Name
Email *

	Sorry, but the email address you supplied was invalid.

Blogs (12)